Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label, active comparator-controlled phase Ⅲ trial to
compare efficacy and safety of Goserelin Acetate Sustained-Release Microspheres for Injection
(LY01005) and ZOLADEX® in patients with breast cancer.